cis-[4-(6-chloropyrazin-2-ylamino)cyclohexyl]carbamic acid tert-butyl ester

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 英文名称: cis-[4-(6-chloropyrazin-2-ylamino)cyclohexyl]carbamic acid tert-butyl ester
• 英文别名: tert-butyl N-[4-[(6-chloropyrazin-2-yl)amino]cyclohexyl]carbamate
• 化学式: C₁₅H₂₃ClN₄O₂
• 分子量: 326.826
• InChiKey: XUUOFTZMAGSDEA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.1
• 重原子数：
  22
• 可旋转键数：
  5
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.67
• 拓扑面积：
  76.1
• 氢给体数：
  2
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  (E)-3-(3-BORONOPHENYL)ACRYLICACID锛圵S203778锛,WUXIAPPTEC" 、 cis-[4-(6-chloropyrazin-2-ylamino)cyclohexyl]carbamic acid tert-butyl ester 在 bis-triphenylphosphine-palladium(II) chloride sodium carbonate 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 0.17h， 生成 (E)-3-{3-[6-(cis-4-tert-butoxycarbonylaminocyclohexylamino)pyrazin-2-yl]phenyl}acrylic acid
  参考文献：
  名称：

  PYRAZINE COMPOUNDS, THEIR USE AND METHODS OF PREPARATION

  摘要：

  该发明提供了根据式(I)的化合物及其用途和制备方法，其中A、X、Y、R1、R2和R3在此处被定义。该发明的化合物抑制参与炎症过程和异常细胞增殖的特定丝氨酸/苏氨酸激酶，因此可用于治疗相关疾病和病理条件，如Pim激酶介导的疾病和涉及炎症的病理条件，包括克罗恩病、炎性肠病、类风湿关节炎和慢性炎症性疾病，或异常细胞增殖，包括各种癌症。

  公开号：

  US20100210627A1
• 作为产物：
  描述：

  2,6-二氯吡嗪 、 tert-butyl cis-4-aminocyclohexylcarbamate 以 N,N-二甲基甲酰胺 为溶剂， 反应 24.0h， 以41%的产率得到cis-[4-(6-chloropyrazin-2-ylamino)cyclohexyl]carbamic acid tert-butyl ester
  参考文献：
  名称：

  PYRAZINE COMPOUNDS, THEIR USE AND METHODS OF PREPARATION

  摘要：

  该发明提供了根据式(I)的化合物及其用途和制备方法，其中A、X、Y、R1、R2和R3在此处被定义。该发明的化合物抑制参与炎症过程和异常细胞增殖的特定丝氨酸/苏氨酸激酶，因此可用于治疗相关疾病和病理条件，如Pim激酶介导的疾病和涉及炎症的病理条件，包括克罗恩病、炎性肠病、类风湿关节炎和慢性炎症性疾病，或异常细胞增殖，包括各种癌症。

  公开号：

  US20100210627A1

文献信息

• PYRAZINE COMPOUNDS, THEIR USE AND METHODS OF PREPARATION
  申请人：Mao Wang

  公开号：US20100210627A1

  公开（公告）日：2010-08-19

  The invention provides compounds according to formula (I) their use and methods for preparation wherein A, X, Y, R1, R2 and R3 are defined herein. The compounds of the invention inhibit specific serine/threonine kinases involved in inflammatory processes and aberrant cell proliferation, and are thus useful for treating associated diseases and pathological conditions such as Pim kinase-mediated diseases and pathological conditions involving inflammation, including Chron's disease, inflammatory bowel disease, rheumatoid arthritis, and chronic inflammatory disease, or aberrant cell proliferation including various cancers.

  该发明提供了根据式(I)的化合物及其用途和制备方法，其中A、X、Y、R1、R2和R3在此处被定义。该发明的化合物抑制参与炎症过程和异常细胞增殖的特定丝氨酸/苏氨酸激酶，因此可用于治疗相关疾病和病理条件，如Pim激酶介导的疾病和涉及炎症的病理条件，包括克罗恩病、炎性肠病、类风湿关节炎和慢性炎症性疾病，或异常细胞增殖，包括各种癌症。
• RHODANINES AND RELATED HETEROCYCLES AS KINASE INHIBITORS
  申请人：HADDACH Mustapha

  公开号：US20100331315A1

  公开（公告）日：2010-12-30

  The invention provides compounds that inhibit PIM kinases and/or CK2, and compositions containing such compounds. These compounds and compositions are useful for treating proliferative disorders such as cancer, as well as other kinase-associated conditions including inflammation, pain, vascular disorders, pathogenic infections and certain immunological disorders.

  该发明提供了能够抑制PIM激酶和/或CK2的化合物以及含有这些化合物的组合物。这些化合物和组合物可用于治疗增殖性疾病如癌症，以及其他与激酶相关的疾病，包括炎症、疼痛、血管疾病、病原体感染和某些免疫性疾病。
• Hit to Lead Account of the Discovery of a New Class of Inhibitors of Pim Kinases and Crystallographic Studies Revealing an Unusual Kinase Binding Mode
  作者：Kevin Qian、Lian Wang、Charles L. Cywin、Bennett T. Farmer、Eugene Hickey、Carol Homon、Scott Jakes、Mohammed A. Kashem、George Lee、Scott Leonard、Jun Li、Ronald Magboo、Wang Mao、Edward Pack、Charlene Peng、Anthony Prokopowicz、Morgan Welzel、John Wolak、Tina Morwick

  DOI：10.1021/jm801242y

  日期：2009.4.9

  A series of inhibitors of Pim-2 kinase identified by high-throughput screening is described. Details of the hit validation and lead generation process and structure-activity relationship (SAR) studies are presented. Disclosure of an unconventional binding mode for 1, as revealed by X-ray crystallography using the highly homologous Pim-1 protein, is also presented, and observed binding features are shown to correlate with the Pim-2 SAR. While highly selective within the kinase family, the series shows similar potency for both Pim-1 and Pim-2, which was expected on the basis of homology, but unusual in light of reports in the literature documenting a bias for Pim-1. A rationale for these observations based on Pim-1 and Pim-2 K(M(ATP)) values is suggested. Some interesting cross reactivity with casein kinase-2 was also identified, and structural features which may contribute to the association are discussed.
• [EN] RHODANINES AND RELATED HETEROCYCLES AS KINASE INHIBITORS<br/>[FR] RHODANINES ET HÉTÉROCYCLES ASSOCIÉS EN TANT QU'INHIBITEURS DE KINASE
  申请人：CYLENE PHARMACEUTICALS INC

  公开号：WO2010148351A1

  公开（公告）日：2010-12-23

  The invention provides compounds that inhibit PIM kinases and/or CK2, and compositions containing such compounds. These compounds and compositions are useful for treating proliferative disorders such as cancer, as well as other kinase-associated conditions including inflammation, pain, vascular disorders, pathogenic infections and certain immunological disorders.